Wed, Mar 4, 2015, 7:36 AM EST - U.S. Markets open in 1 hr 54 mins


% | $
Quotes you view appear here for quick access.

ViroPharma Incorporated Message Board

  • lennox64 lennox64 Oct 17, 2012 4:53 PM Flag

    Plenadren and $42 Price Target

    ViroPharma (NASDAQ: VPHM) is higher Wednesday following positive Germany-initial reimbursement on Plenadren.

    "We believe Plenadren, a new formulation of hydrocortisol for adrenal insufficiency, will achieve $248M in EU sales by 2019 With minimal SGA associated with the product we see Plenadren contributing significantly to EPS," analysts at Deutsche Bank said.

    While new rules in orphan drug reimbursement approval requires new drugs go through the IQWIG, the analyst said Plenadren is exempt by the BDA because: (1) it has the same active ingredient as hydrocortisol, (2) same ATC, and (3) has same method of action as hydrocortisol.

    Plenadren is outside of a reference group, the firm also notes, which is the most positive scenario for Plenadren pricing.

    The firm believes the Street is "underestimating" the earnings leverage with Plenadren and the market opportunity. They are modelling EPS of $2.84 by 2015, which is up from $0.62 in 2013E.

    The reiterated their Buy rating and price target of $42.00.

    Sentiment: Strong Buy

49.96+0.01(+0.02%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.